Recombinant DNA Technology Offers

Yissum - Research Development Company of the Hebrew University posted this:

The Sterile Insect Technique (SIT) to control insect pests is based on their mass-production in dedicated facilities, separation and sterilization of males and their periodic release, in order to compete with wild-type males, and essentially impose female sterility. Their are several problems associated with this procedure: (1) Females tend to soon overcome imposed monogamy, and remate again with males available at that time. Based on research funded by the ISF and the Chief Scientists Fund of the Ministry of Agriculture, we have devised a novel transgenic procedure to prevent or reduce subsequent re-mating of the females in the field, and suppress egg development, which is normally induced by mating. Such transgenic males produce a modified "Sex Peptide", as a component of their seminal fluid, which imposes long-term non-receptivity on females subsequent to initial mating. (2) The second problem is that the current practice of irradiation-imposed sterilization of males is debilitating and reduces their field performance. It is also logistically time-consuming and costly. This situation requires the release of a large overabundance of males (in the case of the Medfly, twice-weekly throughout the year). We propose that irradiation be replaced by genetic sterility and have several suggestion of how this might be approached. The genetic sterility we propose would be incorporated with the persistent modified Sex Peptide, and combined, these two male-specific transgenes would significantly augment the SIT. Project ID : 8-2006-1709

Yissum - Research Development Company of the Hebrew University posted this:

Keywords: cosmetics, sunscreens Project ID : 6-2006-191

Yissum - Research Development Company of the Hebrew University posted this:

CBD Project ID : 6-2017-4448

Yissum - Research Development Company of the Hebrew University posted this:

Many of the antineoplastic tyrosine kinase inhibitors are associated with prominent and sometimes dose-limiting dermatologic complications. Of severe clinical implication are the specific EGFR inhibitors. Most patients treated with these drugs suffer from severe impairment to their quality of life and require reduction or interruption in the anti-cancer drug protocols. Treatment strategies today for treating skin toxicities from EGFR inhibitors show limited benefit and most patients require dose reductions or interruptions to the anti-cancer treatment protocols. Our proposal focuses on the development of a novel approach using formulation for treating skin toxicities caused by anti-neoplastic EGFR inhibitors by applying topical compounds that specifically and locally block the anti-cancer drugs. Our preliminary results have shown that blocking EGFR inhibitors binding to EGFR prevents keratinocyte death. We have identified small compounds that block EGFR inhibitors binding to its receptor and have developed topical slow release system that can deliver the target compounds to the hair follicle which is a major target for skin rash caused by EGFR inhibitors. Our novel approach will improve the quality of life of patients suffering from skin toxicity and help maintain an optimal anti-neoplastic dose thereby allowing more patients to receive full dose anti-cancer therapy and improve response to therapy Project ID : 6-2017-4450